ResearcherFirst Affiliated Hospital of Wenzhou Medical UniversityActive in the last 2 years
Miaomiao Lin
Matched on ORCID iD 0000-0003-2023-7657; OpenAlex author ID A5102941462. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 4
- Correction: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway. Co-author DOI 10.1007/s12094-025-03997-9↗
- Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway. Co-author DOI 10.1007/s12094-023-03328-w↗
- The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… Co-author DOI 10.1038/s41419-022-04573-7↗
- Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… Co-author DOI 10.1038/s41419-022-04705-z↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yanyi Xiao · 4 shared papers, 2022–2025 · strength 0.83
- Paper Correction: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR sign… DOI 10.1007/s12094-025-03997-9↗
- Paper Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathwa… DOI 10.1007/s12094-023-03328-w↗
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Qiyu Zhang · 4 shared papers, 2022–2025 · strength 0.83
- Paper Correction: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR sign… DOI 10.1007/s12094-025-03997-9↗
- Paper Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathwa… DOI 10.1007/s12094-023-03328-w↗
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Zhe Chen · 2 shared papers, 2024–2025 · strength 0.52
- Paper Correction: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR sign… DOI 10.1007/s12094-025-03997-9↗
- Paper Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathwa… DOI 10.1007/s12094-023-03328-w↗
- Hangcheng Guo · 2 shared papers, 2022 · strength 0.30
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Paper Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine ac… DOI 10.1038/s41419-022-04705-z↗
- Hengyue Zhu · 2 shared papers, 2022 · strength 0.30
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Paper Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine ac… DOI 10.1038/s41419-022-04705-z↗
- Yangyang Guo · 2 shared papers, 2022 · strength 0.30
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Paper Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine ac… DOI 10.1038/s41419-022-04705-z↗
- Yongheng Bai · 2 shared papers, 2022 · strength 0.30
- Paper The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, redu… DOI 10.1038/s41419-022-04573-7↗
- Paper Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine ac… DOI 10.1038/s41419-022-04705-z↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.